08:52 AM EDT, 07/08/2025 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Tuesday that it has signed a settlement agreement with Accord Healthcare.

The agreement resolves patent litigation initiated by Esperion against Accord in response to Accord's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Nexletol before the patent expires, Esperion said.

Under the terms of the settlement, Accord has agreed not to sell a generic version of Nexletol in the US before April 19, 2040, Esperion said.

Esperion also said its lawsuits against other generic drugmakers, including Sandoz and Dr. Reddy's Laboratories are still active, with no indication of how they will be resolved.

Shares of Esperion were up 1.8% in recent Tuesday premarket activity.